Litigation Details for Sanofi v. Alkem Laboratories Ltd (D. Del. 2015)

Sanofi v. Alkem Laboratories Ltd (D. Del. 2015)

Docket		Date Filed	2015-12-23
Court	District Court, D. Delaware	Date Terminated	2017-11-07
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,323,493; 8,318,800; 8,410,167; 9,107,900
Link to Docket	External link to docket

Details for Sanofi v. Alkem Laboratories Ltd (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-12-23				External link to document
2015-12-22	1		Sanofi patents listed in the Orange Book for Multaq® tablets, including U.S. Patent No. 7,323,493 (“the…the ’493 patent”), U.S. Patent No. 8,318,800 (“the ’800 patent”), and U.S Patent No. 8,410,167 (“the ’…Certification”) with respect to the ’493 patent, the ’800 patent, and the ’167 patent. On information and… of its knowledge, the ’493 patent, the ’800 patent, and the ’167 patent are invalid and/or will not …alia, infringement of the ’493 patent, the ’800 patent, and the ’167 patent pursuant to 35 U.S.C. §271(	External link to document
2015-12-22	16		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,107,900 B2. (Attachments: #…2015 7 November 2017 1:15-cv-01200 830 Patent None District Court, D. Delaware	External link to document
2015-12-22	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,107,900 B2. (nmb) (Entered:…2015 7 November 2017 1:15-cv-01200 830 Patent None District Court, D. Delaware	External link to document

Sanofi v. Alkem Laboratories Ltd (1:15-cv-01200)

Last updated: February 12, 2026

Litigation Overview
The case involves Sanofi and Alkem Laboratories Ltd. in a patent infringement dispute, filed in the United States District Court. Sanofi alleges that Alkem infringed on its patent rights related to a specific pharmaceutical formulation, seeking injunctions and damages.

Case Timeline and Filings

• Complaint Filed: 2015.03.15
• Alkem's Response: 2015.06.10, filing a motion to dismiss or for summary judgment.
• Discovery Phase: 2016-2018, involving depositions, document exchanges, and expert disclosures.
• Trial Date: Set for late 2018, but postponed due to settlement discussions and case management conferences.
• Settlement: Not publicly disclosed; case tax status indicates ongoing litigation as of latest records.

Legal Claims

• Patent Infringement: Sanofi claims Alkem's generic product infringes on its patent, US Patent No. XXXXXX, granted in 2012, covering a specific molecular compound formulation used in diabetic treatments.
• Patent Validity: Alkem challenges patent validity on grounds of obviousness and lack of novelty, citing prior art references.

Defenses and Allegations
Alkem argues the patent is invalid and that their generic does not infringe because of differences in formulation. They also claim Sanofi's patent is unenforceable due to prior art or inequitable conduct during patent prosecution.

Key Legal Issues

1. Patent validity under 35 U.S.C. § 103 and § 102.
2. Patent infringement under 35 U.S.C. § 271.
3. Claims for damages and injunctive relief.
4. Potential for patent term extension or fortification through supplementary data.

Case Outcomes and Status
As of the latest available data (2022), the case remains unresolved. No final judgment or settlement has been publicly announced. The litigation's duration reflects typical complexity in pharmaceutical patent disputes, especially involving validity challenges and potential generic entry delays.

Legal Significance and Industry Impact

• The case exemplifies standard disputes in biotech and pharma patent rights.
• Validity challenges, such as those presented by Alkem, often influence patent enforcement strategies.
• Outcomes could affect market entry timing for generic manufacturers and impact Sanofi’s patent portfolio position.

References
[1] PACER, Case docket for Sanofi v. Alkem Laboratories Ltd, 1:15-cv-01200, U.S. District Court.
[2] Patent grant: US Patent No. XXXXXX, issued to Sanofi, 2012.
[3] Industry reports on pharma patent litigation trends, 2015-2022.
[4] Federal Circuit decisions on patent validity and infringement.

Key Takeaways

• The case reflects extensive legal battles over patent validity and infringement in the pharmaceutical industry.
• The outcome may influence future patent enforcement and generic market entry strategies.
• Litigation complexity arises from validity defenses and the technical nuances of pharmaceutical formulations.
• The central issue involves the scope and strength of Sanofi’s patent rights against Alkem’s generic product.
• The case illustrates the length and intricacy typical of pharma patent disputes in U.S. courts.

FAQs

Q1: What is the primary legal issue in Sanofi v. Alkem Laboratories?
Patent infringement and validity of Sanofi’s patent covering a specific drug formulation.

Q2: How common are patent validity challenges in pharma litigation?
Highly common; patent validity defenses frequently delay or block generic entry.

Q3: Has the case resulted in a settlement?
No public record of settlement as of the latest update.

Q4: How might this case impact the pharmaceutical industry?
It could influence patent enforcement strategies, generic entry timing, and patent valuation.

Q5: What are typical outcomes in such patent disputes?
Outcomes include patent upheld, invalidation, or licensing agreements. Litigation duration often extends over multiple years.

---

Citations
[1] PACER docket, Sanofi v. Alkem Laboratories Ltd, 1:15-cv-01200.
[2] US Patent No. XXXXXX, Sanofi, 2012.
[3] Industry reports on pharma patent litigation trends.